

Estimate change



TP change



Rating change



Bloomberg	CLGT IN
Equity Shares (m)	272
M.Cap.(INRb)/(USDb)	689.8 / 8.3
52-Week Range (INR)	2550 / 1435
1, 6, 12 Rel. Per (%)	5/30/49
12M Avg Val (INR M)	824

Financials & Valuations (INR b)

Y/E March	2024E	2025E	2026E
Sales	56.5	61.0	65.8
Sales Gr. (%)	8.1	8.0	7.8
EBITDA	18.7	19.5	21.0
EBITDA Margin (%)	33.1	31.9	31.9
Adj. PAT	13.2	13.7	14.8
Adj. EPS (INR)	48.5	50.2	54.4
EPS Gr. (%)	24.7	3.5	8.2
BV/Sh.(INR)	70.9	80.2	92.5

Ratios

RoE (%)	72.4	66.5	63.0
RoCE (%)	70.6	65.0	61.7
Payout (%)	83.6	81.6	77.3

Valuation

P/E (x)	52.3	50.5	46.6
P/BV (x)	35.8	31.6	27.4
EV/EBITDA (x)	36.4	34.8	32.1
Div. Yield (%)	1.6	1.6	1.7

Shareholding pattern (%)

As On	Dec-23	Sep-23	Dec-22
Promoter	51.0	51.0	51.0
DII	5.9	5.9	7.8
FII	24.6	24.1	21.1
Others	18.5	19.4	20.1

FII Includes depository receipts

CMP: INR2,536

TP: INR2,400 (-5%)

Neutral

Unchanged volume trend; margins at all-time high

- Colgate (CLGT) delivered a healthy price-led 8% YoY revenue growth (est. 6%). However, overall volumes experienced a marginal decline (est. +2%). The value growth of toothpaste was in double-digits, while toothbrushes posted YoY decline (weak volume, unfavorable mix). Volume growth for toothpaste was flat to positive. Despite numerous product innovations and marketing efforts, the rebound in volume remains uninspiring.
- The divergence between naturals and traditional oral care products was negligible industry-wide. Despite oral care being less price-sensitive compared to other categories, CLGT implemented a price hike, particularly in the premium segment, by the end of 2QFY24 (mainly in premium) in this market environment.
- Benefiting from softening raw material costs and a revenue growth driven by higher prices, CLGT achieved a record gross margin, reaching 72.2% (up 630bp YoY). In line with the industry trend, the A&P spend was high at 20% YoY. Despite this, CLGT experienced a sharp 550bp YoY expansion in the EBITDA margin, reaching 33.5%. EBITDA grew 30% YoY (-5% was the base).
- We anticipate challenges in FY25, considering our belief that the company may struggle to maintain the current elevated margins. Moreover, the volume pickup in the oral care products will also be slower than the other categories and this is attributed to limited opportunities for penetration and lower frequency of product usage in the oral care segment.
- The recent rally captures the near-term triggers and valuation at 50.5x and 46.6x of P/E on FY25/FY26 does not offer room for valuation play. We maintain our NEUTRAL rating on the stock.

In-line sales; all-time high gross margin

- Colgate (CLGT) sales grew 8.1% YoY to INR13.9b (est. INR13.7b).
- Domestic revenue was up 8.8% YoY; volume was flat to negative (est +2%).
- While some FMCG companies have initiated price cuts to pass on RM benefits (home care, skin cleansing, etc.), Colgate is retaining the benefits and implemented price increases for some products (at premium end).
- However, the pricing strategy is similar within the oral care peers. Thereby, compared to other FMCG companies (seeing price cuts), Colgate's revenue performance stands on the higher side.
- Gross margins increased 630bp YoY and 340bp QoQ to 72.2% (est. 68.4%), reaching an all-time high margin.
- Employee, A&P and other expenses were up 11%, 20%, and 2% YoY.
- As percentage of sales, other expenses stood at 16.1% (down 90bp YoY), advertising expenses at 14.6% (up 150bp YoY), and staff cost at 7.9% (up 20bp YoY).
- EBITDA margin expanded ~550bp YoY to 33.6%.
- EBITDA grew 29.6% YoY to INR4.7b (est. INR4.2b).
- PBT grew 35.6% YoY to INR4.4b (est. INR3.9b).

Naveen Trivedi – Research Analyst (Naveen.Trivedi@motilaloswal.com)

Research Analyst: Pratik Prajapati (pratik.prajapati@motilaloswal.com) | **Tanu Jindal** (Tanu.Jindal@MotilalOswal.com)

Investors are advised to refer through important disclosures made at the last page of the Research Report.

Motilal Oswal research is available on www.motilaloswal.com/Institutional-Equities, Bloomberg, Thomson Reuters, Factset and S&P Capital.

- Adj. PAT grew 35.7% YoY to INR3.3b (est. INR2.9b).
- In 9MFY24 Net sales/EBITDA/adj. PAT growth stood at 8.3%/25.0%/29.1% YoY.

Other takeaways

- Overall volume growth declined marginally; the toothpaste segment saw flat to marginal positive volume growth.
- The price hike was implemented at the end of 2QFY24; full benefits were visible in 3QFY24.
- Toothpaste clocked double-digit revenue growth, whereas toothbrush sales experienced a decline.
- The toothbrush mix was unfavorable, registering a decline in volume growth.
- Volume trajectory is gradually seeing progression, but there is still a degree of caution regarding the recovery in rural markets.
- In categories such as oral care, changes in price and volume are relatively less sensitive compared to home care. Therefore, implementing price cuts may not significantly contribute to the recovery of volumes.
- Natural segment (industry-wide) has witnessed a similar trend with no divergence between natural products and others.
- Gross margin achieved in 9MFY24 (68-69%) are more sustainable than those achieved in 3QFY24 (72%).
- The company remained focused on volume recovery instead of further expanding its operating margin.

Valuation and view

- With a beat on EBITDA margin, we raise our FY24 and FY25 estimates by 5-3% EPS.
- The sales/EBITDA/PAT CAGR for the 10-year period ending FY23 stood at 5%/9%/8%. Despite this, the overall growth seems stagnant, anticipated muted volume growth in the future. Additionally, due to high oral care penetration and competition from herbal players, CLGT has struggled to achieve volume growth for several years. Moreover, premiumization in general trade and traction in personal care have been slow.
- FY25 will be a testing period to check margin trajectory. It seems both gross margin and EBITDA margin have elevated to unsustainable levels. The ongoing debate between prioritizing growth vs. maintaining margins will persist, and to accelerating the growth, margins mat at risk.
- Given the likelihood of continued weak topline and earnings growth in the future, it is unlikely that the stock will undergo a re-rating. We reiterate our Neutral rating on the stock with a **TP of INR2,400** (target multiple of 45x Dec'25E EPS, close to a five-year average).

Quarterly Performance

(INR m)

Y/E March	FY23				FY24E				FY23	FY24E	FY24	Var. (%)
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4QE			3QE	
Volume Gr %	-4.0	-2.5	-2.5	-4.5	3.0	-1.0	-1.0	0.0	-3.4	0.3	2.0	
Net Sales (inclgd. OOI)	11,968	13,875	12,913	13,506	13,237	14,711	13,957	14,574	52,262	56,471	13,744	1.5%
YoY change (%)	-2.9	8.1	10.7	-0.1	10.6	6.0	8.1	7.9	3.8	8.1	6.4	
COGS	4,031	5,029	4,407	4,475	4,179	4,594	3,883	4,287	17,942	16,983	4,345	
Gross Profit	7,938	8,846	8,506	9,031	9,058	10,117	10,073	10,288	34,320	39,488	9,400	7.2%
Gross margin (%)	66.3	63.8	65.9	66.9	68.4	68.8	72.2	70.6	65.7	69.9	68.4	
Other operating Expenses	4,681	4,766	4,891	4,512	4,877	5,295	5,389	5,279	18,850	20,794	5,170	
% to sales	39.1	34.3	37.9	33.4	36.8	36.0	38.6	36.2	36.1	36.8	37.6	
EBITDA	3,257	4,080	3,615	4,519	4,181	4,821	4,684	5,008	15,470	18,694	4,230	10.7%
Margins (%)	27.2	29.4	28.0	33.5	31.6	32.8	33.6	34.4	29.6	33.1	30.8	
YoY growth (%)	-12.1	-3.3	1.8	12.8	28.4	18.2	29.6	10.8	-0.1	20.8	17.0	
Depreciation	442	439	437	431	438	443	414	474	1,748	1,768	482	
Interest	13	13	13	11	11	11	15	14	49	50	14	
Financial other Income	115	113	104	204	150	210	179	162	536	701	135	
PBT	2,918	3,741	3,269	4,281	3,883	4,578	4,434	4,682	14,209	17,577	3,869	14.6%
Tax	727	961	837	1,100	951	1,178	1,133	1,119	3,724	4,375	987	
Rate (%)	24.9	25.7	25.6	25.7	24.5	25.7	25.6	23.9	26.2	24.9	25.5	
Adj PAT	2,167	2,780	2,432	3,175	2,883	3,401	3,301	3,563	10,584	13,202	2,882	14.5%
YoY change (%)	-12.8	-11.6	4.3	18.0	33.1	22.3	35.7	12.2	-0.7	24.7	18.5	

E: MOFSL Estimates


Key Performance Indicators

Y/E March	FY23				FY24			
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4QE
Realization Gr %	1.1	10.6	13.2	4.4	7.6	7.0	9.1	7.9
2Y average growth %								
Volumes	2.0	0.8	-0.8	-4.3	-0.5	-1.8	-1.8	-2.3
Sales	7.8	4.0	2.7	2.6	3.9	7.1	9.4	3.9
EBITDA	4.1	-0.1	-1.2	3.9	8.1	7.5	15.7	11.8
PAT	6.3	1.6	-0.9	1.8	10.2	5.3	20.0	15.1
% sales								
COGS	33.7	36.2	34.1	33.1	31.6	31.2	27.8	29.4
Others	39.1	34.3	37.9	33.4	36.8	36.0	38.6	36.2
Depreciation	3.7	3.2	3.4	3.2	3.3	3.0	3.0	3.3
YoY change %								
COGS	8.2	21.2	22.5	-0.2	3.7	-8.6	-11.9	-4.2
Other income	16.8	70.4	99.8	212.6	29.7	86.3	71.9	-20.5
EBIT	-13.4	-3.2	2.3	14.9	33.0	20.2	34.4	10.9

E: MOFSL Estimates


Key exhibits

Exhibit 1: Overall volume growth marginally declined 1% YoY in 3QFY24




Source: MOFSL

Exhibit 2: Revenue grew 8% YoY to INR14b in 3QFY24




Sources: Company reports, MOFSL

Exhibit 3: Gross margin expanded 630bp YoY to 72.2%




Sources: Company reports, MOFSL

Exhibit 4: EBITDA margin up 550bp YoY to 33.6% in 3QFY24



Sources: Company reports, MOFSL

Exhibit 5: EBITDA increased 29.6% YoY to INR4.7b in 3QFY24



Sources: Company reports, MOFSL

Valuation and view

What happened in the past decade?

- A sharp decline in the market share in the recent years, coupled with increased penetration in the same category, has resulted in single-digit revenue growth over the last 10 years. In recent years, premiumization has declined, adversely affecting realization growth.
- For a company with a modest base of INR31.7b in sales in FY13, a sales/EBITDA/PAT CAGR of 5%/8.8%/7.9% over the last 10 years is indicative of its weak performance.
- Due to a market share decline in the recent years, the sales CAGR has dropped to ~5% over the last five years.

Reiterate Neutral with TP of INR2,400


- With a beat on EBITDA margin, we raise our FY24 and FY25 estimates by 5-3% EPS.
- The sales/EBITDA/PAT CAGR for the 10-year period ending FY23 stood at 5%/9%/8%. Despite this, the overall growth seems stagnant, anticipated muted volume growth in the future. Additionally, due to high oral care penetration and competition from herbal players, CLGT has struggled to achieve volume growth for several years. Moreover, premiumization in general trade and traction in personal care have been slow.
- FY25 will be a testing period to check margin trajectory. It seems both gross margin and EBITDA margin have elevated to unsustainable levels. The ongoing debate between prioritizing growth vs. maintaining margins will persist, and to accelerating the growth, margins mat at risk.
- Given the likelihood of continued weak topline and earnings growth in the future, it is unlikely that the stock will undergo a re-rating. We reiterate our Neutral rating on the stock with a **TP of INR2,400** (target multiple of 45x Dec'25E EPS, close to a five-year average).

Exhibit 6: We increase our EPS estimates for FY24 and FY25 by 5-3%.

	Old		New		Change (%)	
	FY24E	FY25E	FY24E	FY25E	FY24E	FY25E
Sales	56,165	60,900	56,471	60,991	0.5	0.1
EBITDA	17,920	19,109	18,694	19,457	4.3	1.8
PAT	12,495	13,245	13,202	13,664	5.7	3.2


Source: MOFSL

Exhibit 7: P/E ratio (x) for CLGT



Sources: Company reports, MOFSL

Exhibit 8: P/E ratio (x) for the Consumer sector



Sources: Company reports, MOFSL

Financials and valuations

Income Statement						(INR m)		
Y/E March	2019	2020	2021	2022	2023	2024E	2025E	2026E
Net Sales	44,624	45,251	48,412	50,998	52,262	56,471	60,991	65,761
Change (%)	6.6	1.4	7.0	5.3	2.5	8.1	8.0	7.8
Gross Profit	29,039	29,522	32,919	34,323	34,320	39,488	41,739	45,007
Gross Margin (%)	65.1	65.2	68.0	67.3	65.7	69.9	68.4	68.4
EBITDA	12,361	12,017	15,096	15,660	15,470	18,694	19,457	20,978
Change (%)	11.1	-2.8	25.6	3.7	-1.2	20.8	4.1	7.8
Margin (%)	27.7	26.6	31.2	30.7	29.6	33.1	31.9	31.9
Depreciation	1,592	1,979	1,825	1,773	1,748	1,768	1,914	2,059
Int. and Fin. Charges	25	96	73	59	49	50	50	50
Financial Other Income	377	492	304	263	536	701	767	892
Profit before Taxes	11,121	10,434	13,502	14,090	14,209	17,577	18,261	19,761
Change (%)	11.8	-6.2	29.4	4.4	0.8	23.7	3.9	8.2
Margin (%)	24.9	23.1	27.9	27.6	27.2	31.1	29.9	30.1
Tax	3,670	2,269	3,257	3,448	3,724	4,375	4,596	4,974
Deferred Tax	0	-31	-109	-141	-99	0	0	0
Tax Rate (%)	33.0	21.5	23.3	23.5	25.5	24.9	25.2	25.2
Adjusted PAT	7,451	8,196	10,354	10,783	10,584	13,202	13,664	14,787
Change (%)	8.8	10.0	26.3	4.1	-1.8	24.7	3.5	8.2
Margin (%)	16.7	18.1	21.4	21.1	20.3	23.4	22.4	22.5
Non-rec. (Exp)/Income	305	0	0	0	-112	-195	0	0
Reported PAT	7,756	8,196	10,354	10,783	10,472	13,007	13,664	14,787

Balance Sheet						(INR m)	(INR m)	(INR m)
Y/E March	2019	2020	2021	2022	2023	2023	2023	2023
Share Capital	272	272	272	272	272	272	272	272
Reserves	14,196	15,670	11,387	17,075	16,892	19,019	21,531	24,894
Net Worth	14,468	15,942	11,659	17,347	17,164	19,291	21,803	25,166
Loans	978	1,520	1,102	847	820	820	820	820
Deferred Liability	309	50	-48	-173	-288	-288	-288	-288
Capital Employed	15,754	17,512	12,713	18,021	17,695	19,822	22,334	25,698
Gross Block	21,077	22,182	19,831	20,504	21,240	22,990	24,740	26,490
Less: Accum. Depn.	-9,169	-10,953	-9,184	-10,874	-12,622	-14,390	-16,304	-18,362
Net Fixed Assets	11,909	11,229	10,647	9,630	8,618	8,600	8,436	8,127
Capital WIP	1,987	1,900	1,449	1,218	1,141	1,141	1,141	1,141
Investments	312	186	186	0	0	0	0	0
Curr. Assets, L&A	12,058	12,725	16,611	17,997	18,783	21,312	25,106	29,778
Inventory	2,486	2,969	3,358	3,572	3,355	3,629	3,925	4,239
Account Receivables	2,098	1,326	1,171	2,247	1,574	1,700	1,837	1,980
Cash & Bank	3,994	4,213	8,676	7,547	9,230	10,959	13,890	17,643
Others	3,481	4,217	3,405	4,631	4,625	5,023	5,454	5,916
Curr. Liab. and Prov.	10,511	8,528	16,179	10,825	10,846	11,231	12,348	13,348
Account Payables	6,132	6,125	7,604	7,714	7,611	7,815	8,592	9,264
Other Liabilities	3,740	1,798	7,765	2,271	1,953	2,005	2,204	2,377
Provisions	639	605	810	840	1,282	1,411	1,552	1,707
Net Current Assets	1,547	4,197	431	7,173	7,936	10,081	12,757	16,429
Application of Funds	15,754	17,512	12,713	18,021	17,695	19,822	22,334	25,698

E: MOFSL Estimates

Financials and valuations

Ratios

Y/E March	2019	2020	2021	2022	2023	2024E	2025E	2026E
Basic (INR)								
EPS	27.4	30.1	38.1	39.6	38.9	48.5	50.2	54.4
Cash EPS	33.2	37.4	44.8	46.2	45.3	55.0	57.3	61.9
BV/Share	53.2	58.6	42.9	63.8	63.1	70.9	80.2	92.5
DPS	16.0	28.0	38.0	40.0	39.0	40.0	41.0	42.0
Payout %	58.1	93.3	99.8	100.9	101.3	83.6	81.6	77.3

Valuation (x)

P/E	90.7	82.4	65.2	62.6	63.8	51.1	49.4	45.7
Cash P/E	74.7	66.4	55.4	53.8	54.7	45.1	43.3	40.1
EV/Sales	15.1	14.9	13.8	13.1	12.8	11.8	10.9	10.0
EV/EBITDA	54.4	56.0	44.2	42.7	43.1	35.6	34.0	31.4
P/BV	46.7	42.4	57.9	38.9	39.3	35.0	31.0	26.8
Dividend Yield (%)	0.6	1.1	1.5	1.6	1.6	1.6	1.7	1.7

Return Ratios (%)

RoE	50.1	53.9	75.0	74.4	61.3	72.4	66.5	63.0
RoCE	47.3	49.7	68.9	70.5	59.5	70.6	65.0	61.7

Working Capital Ratios

Debtor (Days)	17	11	9	16	11	16	16	16
Asset Turnover (x)	3.3	2.9	4.4	3.0	3.2	3.0	2.9	2.7

Leverage Ratio

Debt/Equity (x)	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0
-----------------	-----	-----	-----	-----	-----	-----	-----	-----

Cash Flow Statement

(INR m)

Y/E March	2019	2020	2021	2022	2023	2024E	2025E	2025E
OP/(loss) before Tax	11,120	10,434	13,502	14,090	14,209	17,382	18,261	19,761
Depreciation	1,592	1,979	1,825	1,773	1,748	1,768	1,914	2,059
Int./Div. Received	53	-96	35	105	68	0	0	0
Interest Paid	-273	-158	-131	-158	-364	50	50	50
Direct Taxes Paid	-4,144	-3,213	-3,584	-3,699	-3,809	-4,375	-4,596	-4,974
(Incr)/Decr in WC	1,494	-35	-3,826	4,151	-89	-149	540	383
CF from Operations	9,842	8,911	7,823	16,261	11,763	14,675	16,168	17,279
(Incr)/Decr in FA	-1,042	-604	-573	-495	-695	-1,750	-1,750	-1,750
Free Cash Flow	8,800	8,307	7,249	15,766	11,068	12,925	14,418	15,529
(Pur)/Sale of Investments	0	7	1,060	-812	221	0	0	0
Others	-1,221	419	5,954	-5,178	1,262	-313	-332	-348
CF from Invest.	-2,263	-177	6,440	-6,485	788	-2,063	-2,082	-2,098
Change in Equity	0	0	0	0	0	0	0	0
(Incr)/Decr in Debt	0	0	0	0	0	0	0	0
Dividend Paid	-7,916	-8,433	-9,211	-10,572	-10,575	-10,880	-11,152	-11,424
Others	-231	-81	-353	-334	-293	-4	-4	-4
CF from Fin. Activity	-8,147	-8,514	-9,565	-10,906	-10,867	-10,884	-11,156	-11,428
Incr/Decr of Cash	-568	219	4,698	-1,129	1,683	1,729	2,931	3,753
Add: Opening Balance	4,562	3,994	3,978	8,676	7,547	9,230	10,959	13,890
Closing Balance	3,994	4,213	8,676	7,547	9,230	10,959	13,890	17,643

E: MOFSL Estimates

Investment in securities market are subject to market risks. Read all the related documents carefully before investing

NOTES

Explanation of Investment Rating	
Investment Rating	Expected return (over 12-month)
BUY	>=15%
SELL	< - 10%
NEUTRAL	< - 10 % to 15%
UNDER REVIEW	Rating may undergo a change
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation

*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall be within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

Disclosures

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on www.motilaloswal.com. MOFSL (erstwhile Motilal Oswal Securities Limited - MOSL) is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL), NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products. Details of associate entities of Motilal Oswal Financial Services Limited are available on the website at <http://online.reports.motilaloswal.com/Dormant/documents/List%20of%20Associate%20companies.pdf>. MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at <https://galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx>

A graph of daily closing prices of securities is available at www.nseindia.com, www.bseindia.com. Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to Subject Company for which Research Team have expressed their views.

Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

For Hong Kong:

This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Securities (SEBI Reg. No. INH000000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

For U.S.

Motilal Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts"), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered/qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

For Singapore

In Singapore, this report is being distributed by Motilal Oswal Capital Markets Singapore Pte Ltd ("MOCMSPL") (Co. Reg. NO. 201129401Z) which is a holder of a capital markets services license and an exempt financial adviser in Singapore. As per the approved agreement under Paragraph 9 of Third Schedule of Securities and Futures Act (CAP 289) and Paragraph 11 of First Schedule of Financial Advisers Act (CAP 110) provided to MOCMSPL by Monetary Authority of Singapore. Persons in Singapore should contact MOCMSPL in respect of any matter arising from, or in connection with this report/publication/communication. This report is distributed solely to persons who qualify as "Institutional Investors", of which some of whom may consist of "accredited" institutional investors as defined in section 4A(1) of the Securities and Futures Act, Chapter 289 of Singapore ("the SFA"). Accordingly, if a Singapore person is not or ceases to be such an institutional investor, such Singapore Person must immediately discontinue any use of this Report and inform MOCMSPL.

Specific Disclosures

- 1 MOFSL, Research Analyst and/or his relatives does not have financial interest in the subject company, as they do not have equity holdings in the subject company.
- 2 MOFSL, Research Analyst and/or his relatives do not have actual/beneficial ownership of 1% or more securities in the subject company
- 3 MOFSL, Research Analyst and/or his relatives have not received compensation/other benefits from the subject company in the past 12 months
- 4 MOFSL, Research Analyst and/or his relatives do not have material conflict of interest in the subject company at the time of publication of research report
- 5 Research Analyst has not served as director/officer/employee in the subject company
- 6 MOFSL has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
- 7 MOFSL has not received compensation for investment banking/ merchant banking/brokerage services from the subject company in the past 12 months
- 8 MOFSL has not received compensation for other than investment banking/merchant banking/brokerage services from the subject company in the past 12 months
- 9 MOFSL has not received any compensation or other benefits from third party in connection with the research report
- 10 MOFSL has not engaged in market making activity for the subject company

The associates of MOFSL may have:

- financial interest in the subject company
- actual/beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public appearance.
- received compensation/other benefits from the subject company in the past 12 months
- any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.
- acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
- be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies)
- received compensation from the subject company in the past 12 months for investment banking / merchant banking / brokerage services or from other than said services.
- Served subject company as its clients during twelve months preceding the date of distribution of the research report.

The associates of MOFSL has not received any compensation or other benefits from third party in connection with the research report

Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures.

Analyst Certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

Terms & Conditions:

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

Disclaimer:

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alternations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, nor its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

This report is meant for the clients of Motilal Oswal only.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 - 71934200 / 71934263; www.motilaloswal.com.

Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai- 400 064. Tel No: 022 71881000. Details of Compliance Officer: Neeraj Agarwal,

Email Id: na@motilaloswal.com, Contact No.:022-40548085.

Grievance Redressal Cell:

Contact Person	Contact No.	Email ID
Ms. Hemangi Date	022 40548000 / 022 67490600	query@motilaloswal.com
Ms. Kumud Upadhyay	022 40548082	servicehead@motilaloswal.com
Mr. Ajay Menon	022 40548083	am@motilaloswal.com

Registration details of group entities.: Motilal Oswal Financial Services Ltd. (MOFSL): INZ000158836 (BSE/NSE/MCX/NCDEX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412 . AMFI: ARN : 146822. IRDA Corporate Agent – CA0579. Motilal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products.

Customer having any query/feedback/ clarification may write to query@motilaloswal.com. In case of grievances for any of the services rendered by Motilal Oswal Financial Services Limited (MOFSL) write to grievances@motilaloswal.com, for DP to dp grievances@motilaloswal.com.